Imatinib and altered bone and mineral metabolism [7]

New England Journal of Medicine

Volumn 355, Issue 6, 2006, Pages 627-

  Owen, Samantha ^a   Hatfield, Alan ^a   Letvak, Laurie ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PHOSPHATE; BIOLOGICAL MARKER; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

BONE METABOLISM; CANCER GRADING; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; HUMAN; HYPOPHOSPHATEMIA; LETTER; MINERAL METABOLISM; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; BLOOD; BONE; CHEMICALLY INDUCED DISORDER; METABOLISM; NOTE; URINE;

BIOLOGICAL MARKERS; BONE AND BONES; HUMANS; HYPOPHOSPHATEMIA; PHOSPHATES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 33746882495     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc061565     Document Type: Letter

References (1)

1. Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006;354:2006-13.